Literature DB >> 18038383

Synthesis of novel migrastatin and dorrigocin A analogues from D-glucal.

Guillaume Anquetin1, Sarah L Rawe, Kevin McMahon, Evelyn P Murphy, Paul V Murphy.   

Abstract

The synthesis of a range of analogues of the migrastatin macrolide core has been achieved from tri-O-acetyl-D-glucal in order to facilitate structure-activity studies. Efficient macrolactone formation was achieved in the presence of a reactive olefin, by increasing steric hindrance in the olefin environment. Acyclic analogues of migrastatin, structurally related to dorrigocin A, have also been prepared from D-glucal. The dorrigocin A analogues were prepared using the combination of the cross metathesis of ethyl 6-heptenoate with a glycal derivative and a subsequent allylic rearrangement-alkene isomerisation reaction (Perlin reaction). A synthetic route is thus provided that will enable dorrigocin A analogues to be prepared in parallel to migrastatin analogues in the search for novel anti-cancer and anti-arthritic therapeutics. Biological evaluation of one migrastatin and one dorrigocin A sugar derived analogue show that they inhibit proliferation and serum-induced migration of tumour and synovial cells at higher concentrations than evodiamine. Dorrigocin A analogues displayed similar potency to analogues of the migrastatin core.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18038383     DOI: 10.1002/chem.200701033

Source DB:  PubMed          Journal:  Chemistry        ISSN: 0947-6539            Impact factor:   5.236


  2 in total

1.  Development of a general, sequential, ring-closing metathesis/intramolecular cross-coupling reaction for the synthesis of polyunsaturated macrolactones.

Authors:  Scott E Denmark; Joseck M Muhuhi
Journal:  J Am Chem Soc       Date:  2010-08-25       Impact factor: 15.419

2.  Migrastatin analogues inhibit canine mammary cancer cell migration and invasion.

Authors:  Kinga Majchrzak; Daniele Lo Re; Małgorzata Gajewska; Małgorzata Bulkowska; Agata Homa; Karol Pawłowski; Tomasz Motyl; Paul V Murphy; Magdalena Król
Journal:  PLoS One       Date:  2013-10-08       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.